-
BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations
Thursday, August 5, 2021 - 11:05am | 375Read More...Novo Nordisk A/S (NYSE: NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Jain upgraded Novo Nordisk from Neutral to Buy and raised his price target from $100.27 to $117.04...
-
AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data
Monday, November 23, 2020 - 3:21pm | 686Read More...AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K. and Brazil, showing efficacy ranging between 62% and 90%. The AstraZeneca Analysts: SVB Leerink analyst Geoffrey Porges has an Outperform rating on...
-
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Friday, April 17, 2020 - 12:49pm | 804Read More...Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...
-
AstraZeneca's Multi-Tumor Opportunity Still Exists
Wednesday, May 18, 2016 - 1:43pm | 295Read More...AstraZeneca plc (ADR) (NYSE: AZN) announced that Lynparza, which has already received approval for ovarian cancer, failed to meet the overall survival endpoint in gastric cancer in the PII GOLD trials. Sachin Jain of Bank of America Merrill Lynch maintains a Buy rating on the company, with a price...
-
Bank Of America Believes DAPT Adds To Precedent For PEGASUS Success For AstraZeneca
Monday, November 17, 2014 - 11:29am | 162Read More...In a report published Monday, Bank of America analyst Sachin Jain reiterated a Buy rating and $80.50 price target on AstraZeneca plc (NYSE: AZN). In the report, Bank of America noted, “The DAPT (dual-antiplatelet therapy) study was presented at the American Heart Association (AHA) congress and...
-
UPDATE: Bank of America Upgrades AstraZeneca plc on Slightly Better Outlook
Monday, October 28, 2013 - 9:02am | 148Read More...In a report published Monday, Bank of America analyst Sachin Jain upgraded the rating on AstraZeneca plc (NYSE: AZN) from Underperform to Neutral, and raised the price target from $48.82 to $55.20. In the report, Bank of America noted, “AZN has underperformed the EU pharma sector by c10% this year...
